Literature DB >> 19013818

Reversible cerebral vasoconstriction syndrome.

Beatrice Garcin1, John Clouston, Noel Saines.   

Abstract

Reversible cerebral vasoconstriction syndrome (RCVS) is an under-recognised condition. It is characterised by sudden and severe headaches (of "thunderclap" type) associated with multifocal reversible narrowing of the intracranial arteries on neuroradiology. The diagnosis is often established with the resolution of headaches and vasoconstriction. We report two patients with RCVS and review the available literature, to clarify the diagnostic criteria and discuss the treatment options.

Entities:  

Mesh:

Year:  2008        PMID: 19013818     DOI: 10.1016/j.jocn.2008.03.014

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  5 in total

Review 1.  Reversible cerebral vasoconstriction syndrome (RCVS) in antiphospholipid antibody syndrome (APLA): the role of centrally acting vasodilators. Case series and review of literature.

Authors:  Sarthak Gupta; Robert Zivadinov; Deepa Ramasamy; Julian L Ambrus
Journal:  Clin Rheumatol       Date:  2013-11-26       Impact factor: 2.980

Review 2.  Reversible cerebral vasoconstriction syndrome: updates and new perspectives.

Authors:  Huma U Sheikh; Paul G Mathew
Journal:  Curr Pain Headache Rep       Date:  2014-05

Review 3.  Reversible cerebral vasospasm, multilobular intracerebral hemorrhages, and nonaneurysmal subarachnoid hemorrhage: review of possible interrelationships.

Authors:  Philippe Hantson; Patrice Forget
Journal:  Curr Pain Headache Rep       Date:  2010-06

4.  Reversible Cerebral Vasoconstriction Disorder in a Patient with a Chief Complaint of Headache.

Authors:  Simran Buttar; Anuja Trivedi; Dimitrios Papanagnou
Journal:  Cureus       Date:  2018-04-16

5.  Dramatic intracerebral hemorrhagic presentations of reversible cerebral vasoconstriction syndrome: three cases and a literature review.

Authors:  Joel M Stary; Bonnie H Wang; Seong-Jin Moon; Huan Wang
Journal:  Case Rep Neurol Med       Date:  2014-01-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.